

Cite this: *RSC Adv.*, 2017, 7, 44447

A novel information fusion strategy based on a regularized framework for identifying disease-related microRNAs

Li Peng,^{ab} Manman Peng,^{*a} Bo Liao,^a Qiu Xiao,^a Wei Liu,^{cd} Guohua Huang^d and Keqin Li^e

Abnormal microRNA (miRNA) expression can induce various complex human diseases. Thus, revealing the underlying relationship between miRNA and human diseases contributes to the early diagnosis and treatment of diseases. Utilizing a computational approach in selecting the most likely miRNA candidates related to a given disease for further biological experimental validation can save time and manpower costs. In this study, we propose a novel information fusion strategy called RLSSLP, which is based on a regularized framework, for discovering the underlying associations between miRNAs and diseases. RLSSLP integrates two submodels to construct effective prediction frameworks and quantify the similarities between miRNAs and diseases by fully using multiple omics data, which include verified associations, particularly miRNA–disease, miRNA–gene, and weighted gene–gene network associations. The 10-fold cross-validation and case studies for lung cancer, hepatocellular carcinoma and breast cancer indicate that RLSSLP performs well in predicting miRNA–disease interactions.

Received 11th August 2017
Accepted 7th September 2017

DOI: 10.1039/c7ra08894a

rsc.li/rsc-advances

Introduction

MiRNAs are a set of small non-protein-coding RNAs and approximately 22 nt long.^{1,2} MiRNAs are involved in many crucial pathological and biological processes. Thus, abnormal miRNA expression can induce various complex human diseases, including cancer.^{3,4} Revealing the underlying relationships between miRNA and human diseases contributes to the early diagnosis and treatment of diseases. However, traditional experimental methods for detecting disease-related miRNAs require huge amounts of time and manpower. Utilizing computational approaches in selecting miRNA candidates that are likely related to a particular disease for further biological experimental validation is more efficient than traditional approaches and costs less.

In recent years, many efforts have been extensively exerted to investigate the associations between miRNAs and diseases. Some network-based methods that predict miRNA–disease interactions are based on the hypothesis that similar miRNAs

are likely to relate to similar diseases, and *vice versa*. Jiang *et al.*⁵ first proposed a similarity-based approach that measures miRNA functional similarity based on the common sets of their associated target gene and identify disease-related miRNAs based on hypergeometric distributions. Shi *et al.*⁶ investigated the relationships of miRNA–target and disease–gene and constructed a bipartite network for discovering the miRNA regulation of disease gene. However, due to the false-positive rate in target predictions, the accuracy of the above methods is often negatively affected. Xuan *et al.*⁷ proposed a new method called HDMP, which sorts the most likely miRNA candidates related to diseases according to the weighted *k* most similar neighbor. Chen *et al.*⁸ presented “RWRMDA: predicting novel human microRNA–disease associations”, which is a predictive approach wherein the algorithm of random walk with restart is applied to construct a global network for capturing underlying miRNA–disease associations. Li *et al.*⁹ presented a new computational method based on the algorithm of matrix completion to recover the associations score of each miRNA–disease pair. However, these methods cannot be used to predict diseases with no known related miRNAs.

Some classical machine learning methods were also utilized for mining the relationship between miRNAs and diseases. Jiang *et al.*¹⁰ advanced a computational approach based on Naïve Bayes for discovering disease-associated miRNAs. Xu *et al.*¹¹ presented a method, which applied support vector machine in distinguishing associated or nonassociated miRNAs for particular diseases. However, one weakness of these approaches is that the negative samples utilized in these

^aCollege of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China. E-mail: plpeng@hnu.edu.cn; pengmanman@hnu.edu.cn^bCollege of Computer Science and Engineering, Hunan University of Science and Technology, Xiangtan, Hunan, 411201, China^cCollege of Information Engineering, XiangTan University, Xiangtan, Hunan, 411105, China^dCollege of Information Engineering, Shaoyang University, Shaoyang, Hunan, 422000, China^eDepartment of Computer Science, State University of New York, New Paltz, New York 12561, USA

machine-learning methods are practically hard to obtain because verified nonassociations between miRNAs and diseases cannot be found exactly in any existing database.

By incorporating experimentally verified miRNA–disease associations and diverse similarity information based on miRNAs and diseases into a heterogeneous graph, Chen *et al.*¹² advanced a novel approach named HGIMDA to infer underlying relationship between miRNAs and diseases. You *et al.*¹³ presented a path-based prediction method, named PBMDA, which applied depth-first search algorithm in the integrated heterogeneous graph to capture the potential miRNA–disease associations. Chen *et al.*¹⁴ developed a new method named WBSMDA, which predicted miRNA–disease interactions based on the framework of within and between score. They also proposed a computational approach named SDMMDA¹⁵ based on super-disease and super miRNA to predict underlying miRNA–disease interactions. “RBMMDA: predicting multiple types of disease-microRNA associations”, which proposed by Chen *et al.*,¹⁶ is the first model that can predict not only whether there is a link between each miRNA and disease pairs, but also the corresponding type of association.

Zou *et al.*¹⁷ presented a method called KATZ for predicting miRNA–disease interactions. In this method, social network analysis methods are adopted to construct miRNA–disease association networks. However, although KATZ has excellent performance, its capability to spare known associations is relatively poor. Chen *et al.*¹⁸ presented a semi-supervised approach, called RLSMDA, for exposing unknown miRNA–disease interactions on the basis of regularized least squares. Luo *et al.*¹⁹ utilized heterogeneous omics data and adopted Kronecker regularized least-squares framework to identify potential disease-related miRNAs. However, cross-validation performance of these methods is not so good.

Overall, the aforementioned approaches have the following limitations: some methods cannot predict diseases without known related miRNAs, some methods require negative samples that are practically hard to obtain, and exhibit predictive performance that requires further improvement.

To overcome the above challenges, we proposed a novel information fusion strategy called RLSSLP, which is based on a regularized framework, for discovering underlying associations between miRNAs and diseases. RLSSLP comprehensively measures the similarity for miRNAs and diseases by fully using the multiple omics data, which include known miRNA–disease interactions, gene–gene networks, and the experimentally verified association data of miRNA–gene from three different databases. RLSSLP adopts the eigenvalue transformation technique to reduce computational time and memory requirement, as well as utilizes integrated regularized framework based on regularized least squares (RLS)^{18,19,29} and semi-supervised link prediction (SLP)^{20,30} to prioritize disease-related miRNAs.

The main contributions of this study are as follows:

- (1) RLSSLP does not need negative training samples, which are practically hard to obtain.
- (2) Various omics data can be fully utilized in RLSSLP and are beneficial for comprehensive evaluation of the similarities between miRNAs and diseases. MiRNA–gene association data

are obtained from three different experimentally verified databases, which help reduce influence of false-positive rate on the performance of the miRNA–target prediction process.

- (3) Eigenvalue transformation technique has been adopted to reduce computational time and memory requirement for the storage and calculation between the similarities matrices during the Kronecker operation.

- (4) Two submodels are combined in RLSSLP to enhance predictive performance.

Materials and methods

Data preparation

The standard dataset used in our study include data on known miRNA–disease associations, disease similarities, and relevant information about miRNA similarities. MiRNA–disease associations are retrieved from HMDD v2.0.²¹ After duplicated associations are filtered, the data contain 5424 experimentally verified interactions, which consist of 495 miRNAs and 378 diseases. Disease directed acyclic graph (DAG), which is used to calculate disease semantic similarities, is derived from the MeSH database (available from: <https://www.nlm.nih.gov/mesh/>). We obtain miRNA target genes from the miRTarBase v4.5,²² TarBase v6.0,²³ and miRecords v4.0 (ref. 24) to obtain more accurate and comprehensive information. The probabilistic functional gene network is obtained from HumanNet²⁵ (available from: <http://www.functionalnet.org/humannet/>).

Problem description

The problem can be regard as predicting novel interactions in a miRNA–disease association network. Formally, $X_m = \{m_1, m_2, \dots, m_{n_m}\}$ and $X_d = \{d_1, d_2, \dots, d_{n_d}\}$ represent the sets of miRNA and disease nodes, respectively. The known miRNA–disease association network is characterized as $n_m \times n_d$ adjacency matrix pre. If miRNA i interacts with disease j , pre_{ij} is 1; otherwise, 0. In this study, we calculate the prediction score of each unknown miRNA–disease pair though a computational approach and recover the underlying association between miRNAs and diseases.

Disease similarity calculation

Accumulating findings show that miRNAs with similar functions tend to regulate similar diseases. In this work, the method for estimating disease semantic similarities was based on the strategy of Wang *et al.*²⁶

In MeSH database, diseases can be expressed into a DAG. Formally, disease i can be denoted as $\text{DAG}(i) = (i, T_i, E_i)$, where T_i is the disease set containing i itself and all its ancestors, and E_i represents the sets of corresponding links of disease i . The semantic contribution of ancestor node t to disease i is as follows:

$$\begin{cases} D_i(i) = 1 \\ D_i(t) = \max\{\Delta \times D_i(t') \mid t' \in \text{children of } t\} & \text{if } t \neq i. \end{cases} \quad (1)$$

where, Δ is the semantic contribution factor, and according to Wang *et al.*, the value of Δ is 0.5.



The semantic similarity score between disease i and j is denoted as follows:

$$S_D(i, j) = \frac{\sum_{t \in T_i \cap T_j} (D_i(t) + D_j(t))}{\sum_{t \in T(i)} D_i(t) + \sum_{t \in T(j)} D_j(t)} \quad (2)$$

where, $\sum_{t \in T(i)} D_i(t)$ and $\sum_{t \in T(j)} D_j(t)$ are the semantic value of disease i and disease j , respectively. As shown in eqn (2), the two diseases share a common part of DAG, the semantic similarity score is high, and the two diseases are increasingly similar.

MiRNA similarity calculation

The more the two miRNAs share target genes, the more similar they are. In this work, we measure the similarities for miRNA according to an experimentally validated miRNA–target gene relationship and probabilistic functional gene network.

First, we extract the common miRNA–target gene set from three experimentally valid databases mentioned above. The gene–gene relationship network can be acquired from HumanNet, in which the closeness of the link between each pair of genes is measured by associated log-likelihood scores. $S_L(e_i, e_j)$ stands for the associated log-likelihood scores between genes e_i and e_j . Second, we normalize $S_L(e_i, e_j)$ and obtain the normalized similarity $S_{L_{\text{norm}}}(e_i, e_j)$ between genes e_i and e_j as follows:

$$S_{L_{\text{norm}}}(e_i, e_j) = \frac{S_L(e_i, e_j) - S_{L_{\min}}}{S_{L_{\max}} - S_{L_{\min}}} \quad (3)$$

where, $S_{L_{\max}}$ and $S_{L_{\min}}$ indicate the maximum and minimum log-likelihood scores in HumanNet, respectively. If a functional linkage exists between genes e_i and e_j , then the functional similarity $S_G(e_i, e_j)$ between gene e_i and gene e_j is $S_{L_{\text{norm}}}(e_i, e_j)$. Otherwise, it defaults to 0. In addition, when $i = j$, the similarity score is 1.

The similarity between genes e_t and gene set $E = \{e_{t1}, e_{t2}, \dots, e_{tk}\}$ is provided as follows:

$$S(e_t, E) = \max_{1 \leq i \leq k} (S_G(e_t, e_i)) \quad (4)$$

Finally, basing on a best matching average (BMA) strategy,^{27,28} we calculate the functional similarity between miRNAs i and j according to common genes.

$$S_M(i, j) = \frac{\sum_{1 \leq i \leq |E_1|} S(e_i, E_2) + \sum_{1 \leq i \leq |E_2|} S(e_i, E_1)}{|E_1| + |E_2|} \quad (5)$$

where, E_1 and E_2 represent the gene set related to miRNA i and j , respectively.

Methods for miRNA–disease interaction prediction

In our study, we apply an information fusion strategy and combine RLS and SLP to establish a prediction model. The overall flowchart of RLSSLP is shown in Fig. 1.

Part 1: RLS model for uncovering miRNA–disease interaction. RLS is an effective supervised learning algorithm, which can achieve good performance if an appropriate kernel has been selected. To uncover the potential associations between miRNA–diseases, the objective function of RLS can be defined as follows (notice that, $\text{vec}(\text{pre}_1)$ is the vectorization operation of matrix pre_1):

$$\min_{c \in R} \frac{1}{2I} \|\text{vec}(\text{pre}_1) - Sc\|_2^2 + \frac{\lambda}{2} c^T Sc \quad (6)$$

In this study, λ is a regularization parameter. Kernel matrix S is defined as $S = S_M \otimes S_D$, which represents the Kronecker product of miRNA similarity matrix S_M and disease similarity matrix S_D . Through the derivative of c , the optimal solution of c is $c = (S + \sigma I)^{-1} \text{vec}(\text{pre})$, where $\sigma = \lambda I$. I is the identity matrix. The prediction association score matrix $\overline{\text{pre}}_1$ is calculated as follows:

$$\text{vec}(\overline{\text{pre}}_1) = Sc = S(S + \sigma I)^{-1} \text{vec}(\text{pre}_1) \quad (7)$$

Part 2: SLP model for uncovering miRNA–disease interactions. Basing on the SLP algorithm,²⁰ in which two similar nodes are assumed to share the same link strength, we obtain the objective function for miRNA–disease association prediction as follows:

$$\min_{\text{pre}} \frac{\sigma}{2} \text{vec}(\overline{\text{pre}}_2)^T L \text{vec}(\overline{\text{pre}}_2) + \frac{1}{2} \|\text{vec}(\overline{\text{pre}}_2) - \text{vec}(\text{pre}_2)\|_2^2 \quad (8)$$

where, the first term denotes that the prediction score $[\overline{\text{pre}}]_{ij}$ and $[\overline{\text{pre}}]_{lm}$ for the two pairs (for instance, the association between miRNA i –disease j and miRNA l –disease m) should be close to each other if some significant similarities between the two pairs are present. The second term is a regularization term and represents the loss function that fits the prediction matrix $\overline{\text{pre}}_2$ to known miRNA–disease association matrix pre_2 . Parameter σ represents the regularization parameter to balance the two terms. The Laplacian matrix L is denoted as $L = I - S_M \otimes S_D$. Specifically, L can be denoted as

$$L = I - \left(D_M^{-\frac{1}{2}} S_M D_M^{-\frac{1}{2}} \right) \otimes \left(D_D^{-\frac{1}{2}} S_D D_D^{-\frac{1}{2}} \right) \quad (9)$$

where, D_M and D_D are the diagonal matrices in which their diagonal elements are $[D_M]_{ii} = \sum_j [S_M]_{ij}$ and $[D_D]_{ii} = \sum_j [S_D]_{ij}$, respectively.

Therefore, the prediction score matrix $\overline{\text{pre}}_2$ is calculated as follows:

$$\text{vec}(\overline{\text{pre}}_2) = (\sigma L + I)^{-1} \text{vec}(\text{pre}_2) \quad (10)$$

Information fusion strategy (RLSSLP)

In general, we can directly use conjugate gradient-based method³⁰ to solve eqn (7) and (10). However, an unavoidable limitation exists due to the large memory requirements and computational time for storing the matrices, which include S_M ,






Fig. 1 The overall flowchart of RLSSLP.

S_D , \overline{pre}_1 and \overline{pre}_2 during the Kronecker operation. Therefore, we perform the eigenvalue transformation technique³¹ to improve the calculation efficiency and further extend its application on large-size miRNA-disease association network.

Step 1: improving RLS with eigenvalue transformation. Let $S_M = R_M \Lambda R_M^T$ and $S_D = R_D \Lambda R_D^T$ be the Eigen decompositions of matrix S_M and S_D . Then the kernel matrix S in RLS model can be denoted as $S = S_M \otimes S_D = R \Lambda R^T$, where $R = R_M \otimes R_D$ and $\Lambda = \Lambda_M \otimes \Lambda_D$. Based on the property of Kronecker product, we can transform eqn (7) into:

$$\begin{aligned} \text{vec}(\overline{pre}_1) &= S(S + \sigma I)^{-1} \text{vec}(pre_1) = R \Lambda (R + \sigma I)^{-1} R^T \text{vec}(pre_1) \\ &= R Z R^T \text{vec}(pre_1) \end{aligned} \quad (11)$$

where, Z is a diagonal matrix and its diagonal elements are $[Z]_{ii} = \lambda_i / (\lambda_i + \sigma)$; λ_i is an eigenvalue of S . We apply a simple eigenvalue transformation as $f(\lambda_i) = \lambda_i^\alpha$ and replace λ_i with λ_i^α in eqn (11). Therefore, we can rewrite the new prediction score matrix \overline{pre}_1 after eigenvalue transformation:

$$\text{vec}(\overline{pre}_1) = R \bar{Z} R^T \text{vec}(pre_1) \quad (12)$$

where, \bar{Z} is a diagonal matrix and its diagonal elements are $[\bar{Z}]_{ii} = \lambda_i^\alpha / (\lambda_i^\alpha + \sigma)$.

Step 2: improving SLP with eigenvalue transformation. We use $\bar{S} = \bar{R} \bar{\Lambda} \bar{R}^T$ as the Eigen decomposition of matrix \bar{S} for SLP. Then eqn (10) can be rewritten as:

$$\text{vec}(\overline{pre}_2) = ((\sigma + 1)I - \sigma \bar{S}) \text{vec}(pre_2) = \bar{R} \bar{Z} \bar{R}^T \text{vec}(pre_2) \quad (13)$$

where \bar{Z} is a diagonal matrix and its diagonal elements are $[\bar{Z}]_{ii} = 1 / (1 + \sigma - \sigma \lambda_i)$ and λ_i is an eigenvalue of \bar{S} .

Similar to RLS, after the transformation of the eigenvalue, the new prediction matrix \overline{pre}_2 in SLP is as follows:

$$\text{vec}(\overline{pre}_2) = \bar{R} \bar{Z} \bar{R}^T \text{vec}(pre_2) \quad (14)$$

where, $[\bar{Z}]_{ii} = 1 / (1 + \sigma - \sigma \lambda_i^\alpha)$ is a diagonal matrix and its diagonal elements are $[\bar{Z}]_{ii} = 1 / (1 + \sigma - \sigma \lambda_i^\alpha)$.

Step3: combining the two submodels

Finally, we combine the new prediction score matrix \overline{pre}_1 and \overline{pre}_2 after the eigenvalue transformation. The prediction matrix is obtained as follows:

$$\text{vec}(\overline{pre}) = \frac{1}{2} (\text{vec}(\overline{pre}_1) + \text{vec}(\overline{pre}_2)) \quad (15)$$



The more miRNA i strongly associates with disease j , the higher the corresponding prediction score $\overline{\text{pre}}_{ij}$ is.

The eigen decompositions of similarity matrix S_M and S_D are one of the key technique in this paper to efficiently compute the inverse matrix on the eqn (6) and (8) that involves Kronecker operators. By applying this technique, the time complexity of the RLS sub-model is reduced from $O((n_m \times n_d)^3)$ to $O((n_m)^3 + (n_d)^3)$, in which n_m and n_d represent the number of miRNAs and diseases, respectively. Moreover, the time complexity of the SLP sub-model is $O((n_m)^3 + (n_d)^3 + n_m \cdot n_d)$, more detail can be found from ref. 14. Thus, the total time complexity is $O((n_m)^3 + (n_d)^3 + n_m \cdot n_d)$.

Results

Performance evaluation of RLSSLP

In this section, we implement a 10-fold cross-validation on the standard dataset to evaluate the performance of RLSSLP and other compared methods. In the experiment, both known and unknown miRNA–disease interactions are randomly divided into 10 subsets of equal sizes. In each repetition of the method, one subset of known miRNA–disease interactions and one of unknown interactions are selected (their scores in the adjacency matrix pre were set to 0) as test sets. We use the remaining nine subsets as training sets to recover the prediction score matrix. The value of area under the curve (AUC receiver operating characteristic (ROC)) is used as the main quantitative index for performance evaluation.

Basing on the RLS and SLP models, we apply information fusion strategy and eigenvalue transformation technique to construct a global prediction framework to uncover potential miRNA–disease interactions. We evaluate the predictive performance of RLSSLP by considering the following aspects: (1) RLSSLP with information fusion strategy and eigenvalue transformation technique, (2) RLSSLP with RLS model only, and (3) RLSSLP with SLP model only. The ROC curves and average AUC values of RLSSLP at different situations mentioned above are displayed in Fig. 2.

As illustrated in Fig. 1, RLSSLP exhibited desirable predictive performance and achieved an AUC value of 0.9265. The AUC values for the RLS model and SLP models are 0.8992 and 0.8735, respectively. The RLSSLP framework of the combined information increases the AUC value, which is 2.73% and 5.30% higher compare with those of the RLS and SLP models, respectively. Evidently, the information fusion strategy and eigenvalue transformation technique enhance the predictive ability of RLSSLP.

Effect of parameter on RLSSLP performance

Parameters σ and α are introduced in the RLSSLP method. Parameter σ is the regularization parameter for the RLS and SLP models and balances the first and second terms in each regularization framework. Parameter α is an eigenvalue exponent and influences the improvement performance attributed to the application of the eigenvalue transformation technique. In this study, we set σ to 0.05 for the RLS model and 0.01 for SLP model




Fig. 2 ROC curve and average AUC value of RLSSLP in different situations. (1) RLSSLP after information fusion strategy, (2) RLS only, (3) SLP only.

in a noninformative manner according to a previous study.³² To explore the influence of parameter α on predictive performance, we fix regularization parameter σ and vary the value of α from 0 to 2 with an interval of 0.1 in the 10-fold cross-validation experiments. Fig. 3 shows the average AUC obtained from RLSSLP at different values of α . When we set the value of α from 0 to 2, the AUC value fluctuates between 0.6987 and 0.9450. When $\alpha = 1.3$, RLSSLP has an optimal AUC value. More remarkably, when $\alpha = 1$, the algorithm is equal to the original algorithm without applying the eigenvalue transformation technique.

Comparison with other methods

To the best of our knowledge, RWRMDA, RLSMDA, KATZ, HDMP, and KRLSM are the representative computer methods for the prediction of miRNA–disease associations. Given that RWRMDA and HDMP cannot predict diseases with no related miRNAs, we compared RLSSLP with RLSMDA, KATZ, and KRLSM.

We implement a 10-fold cross-validation for RLSSLP and three other methods. The optimal parameters of RLSMDA, KATZ, and KRLSM are selected as described in literature. The ROC curves and AUC values of the four methods are shown in Fig. 4. The average AUC values of RLSSLP, RLSMDA, KATZ, and KRLSM are 0.9250, 0.8547, 0.9081, and 0.8324, respectively.




Fig. 3 The effect of parameters α on the RLSSLP.






Fig. 4 Comparison among RLSSLP, RLSMDA, KATZ, and KRLSM with respect to their ROC curves and average AUC values obtained through the 10-fold cross-validation.

RLSSLP has the best prediction result, and its average AUC value is increased and is 7.03%, 1.69%, and 9.26% higher than the other three approaches. The comparison results demonstrate that RLSSLP performs better than RLSMDA, KATZ, and KRLSM during the 10-fold cross-validation.

Case studies

Few miRNAs play a crucial regulatory role in various human cancers. Case studies for breast, hepatocellular carcinoma (HCC), and lung cancer were implemented to evaluate the capability of RLSSLP to discover disease-related miRNA candidates. All the known miRNA–diseases interactions in the standard dataset were assigned as training sets, and the remaining unknown interactions served as testing sets. The predictive disease-related miRNAs were confirmed by public databases dbDEMC³³ and miRCancer.³⁴

Lung cancer is one of the primary cancers that kill thousands of people annually. Early diagnosis and intervention can improve the low survival rate of patients with lung cancer. Many researchers reported that miRNAs, such as let-7e, mir-21, mir-25, mir-223, and mir-486, are potential premonitory biomarkers for lung cancer.³⁵ In particular, Mir-145 inhibits tumor cell proliferation and is known to act as a tumor suppressor. Meanwhile, miRNA-192, miRNA-200c, and mir-21 are overexpressed during the progression of lung neoplasms.³⁶ The top 20 potential miRNA candidates associated with lung cancer and predicted by RLSSLP are listed in Table 1. Of these candidates, 17 are verified by the dbDEMC and miRCancer databases to be associated with lung neoplasms. Meanwhile, three are not verified on these two databases, although we find that mir-296 suppresses cell viability in lung cancer³⁷ (PMID: 26549165).

Meanwhile, HCC is the most common form of liver cancer. Analyzing miRNA expression data in cancerous liver tissues and normal tissues may facilitate the discovery of novel miRNA

Table 1 Top 20 potential lung cancer-related miRNAs predicted by RLSSLP and their confirmed interactions. Seventeen of the top 20 miRNA candidates related to lung neoplasms have been verified on dbDEMC and miRCancer databases

Rank	miRNA name	Evidences
1	hsa-mir-708	dbDEMC
2	hsa-mir-149	dbDEMC
3	hsa-mir-625	dbDEMC
4	hsa-mir-429	miRCancer, dbDEMC
5	hsa-mir-296	Unconfirmed
6	hsa-mir-302b	miRCancer, dbDEMC
7	hsa-mir-520b	dbDEMC
8	hsa-mir-92b	dbDEMC
9	hsa-mir-193b	dbDEMC
10	hsa-mir-378a	Unconfirmed
11	hsa-mir-20b	dbDEMC
12	hsa-mir-204	dbDEMC
13	hsa-mir-302c	dbDEMC
14	hsa-mir-151a	Unconfirmed
15	hsa-mir-345	dbDEMC
16	hsa-mir-367	dbDEMC
17	hsa-mir-302d	dbDEMC
18	hsa-mir-99a	dbDEMC
19	hsa-mir-139	dbDEMC
20	hsa-mir-211	dbDEMC

biomarkers and may assist the early detection of HCC cancer state. For instance, the expression levels of mir-125a, let-7e, mir-99b, and mir-195 are lower in HCC neoplasm tissues compared with those in normal liver tissues.³⁸ Mir-92, mir-20, mir-100, mir-10a, mir-122, and mir-222 are more overexpressed in HCC tumor tissues compared with those in nontumor liver tissues.³⁹ The top 20 potential HCC-related miRNAs predicted by RLSSLP and their confirmed interactions are listed in Table 2. All these

Table 2 Top 20 potential hepatocellular carcinoma-related miRNAs predicted by RLSSLP and their confirmed interactions. All of the top 20 miRNA candidates related to hepatocellular carcinoma have been verified on dbDEMC and miRCancer databases

Rank	miRNA name	Evidences
1	hsa-mir-185	miRCancer, dbDEMC
2	hsa-mir-302d	dbDEMC
3	hsa-mir-135b	dbDEMC
4	hsa-mir-520h	dbDEMC
5	hsa-mir-302a	dbDEMC
6	hsa-mir-429	miRCancer, dbDEMC
7	hsa-mir-367	miRCancer, dbDEMC
8	hsa-mir-204	miRCancer, dbDEMC
9	hsa-mir-638	miRCancer, dbDEMC
10	hsa-mir-708	miRCancer
11	hsa-mir-149	miRCancer, dbDEMC
12	hsa-mir-215	miRCancer, dbDEMC
13	hsa-mir-331	miRCancer, dbDEMC
14	hsa-mir-625	miRCancer
15	hsa-mir-186	dbDEMC
16	hsa-mir-371a	miRCancer, dbDEMC
17	hsa-mir-211	miRCancer, dbDEMC
18	hsa-mir-95	miRCancer, dbDEMC
19	hsa-mir-194	miRCancer, dbDEMC
20	hsa-mir-30e	miRCancer, dbDEMC



Breast cancer is another type of cancer that seriously affects people's health, especially women. Few miRNAs are involved in the regulation of some critical processes in breast cancer

Rank	miRNA name	Evidences
1	hsa-mir-186	dbDEMC
2	hsa-mir-330	dbDEMC
3	hsa-mir-130a	miRCancer, dbDEMC
4	hsa-mir-185	miRCancer, dbDEMC
5	hsa-mir-449a	dbDEMC
6	hsa-mir-99a	dbDEMC
7	hsa-mir-106a	miRCancer, dbDEMC
8	hsa-mir-95	dbDEMC
9	hsa-mir-142	Unconfirmed
10	hsa-mir-449b	dbDEMC
11	hsa-mir-650	dbDEMC
12	hsa-mir-574	miRCancer
13	hsa-mir-98	miRCancer, dbDEMC
14	hsa-mir-376a	dbDEMC
15	hsa-mir-130b	dbDEMC
16	hsa-mir-381	miRCancer, dbDEMC
17	hsa-mir-32	dbDEMC
18	hsa-mir-99b	dbDEMC
19	hsa-mir-542	Unconfirmed
20	hsa-mir-487b	dbDEMC

progression, such as proliferation and apoptosis of breast neoplasm cell. For instance, mir-99a, mir-24, mir-101, mir-152, mir96, and the let-7 family are involved in the development of breast cancer.^{40,41} The top 20 potential breast neoplasm-related miRNAs predicted by RLSSLP and their confirmed interactions are listed in Table 3. Among these candidates, 18 were verified on dbDEMC and miRCancer databases, and only 2 miRNAs were unconfirmed. However, ref. 42 (PMID: 26657485) proved that mir-142 inhibits the invasiveness of human breast neoplasm cell. In addition, ref. 43 (PMID: 28121348) investigated that mir-542 regulates the proliferation and invasion of breast tumor cell.

Finally, we implement another experiment on an isolated disease (diseases without known related miRNAs) to demonstrate the strength of our method. We remove known verified miRNAs related to three diseases discussed above and predict potential miRNA candidates associated with a particular disease by only using similarity information and associations of other diseases. Consequently, the average AUC value of RLSSLP for the prediction of isolated diseases is 0.8175. Fig. 5 displays the predicted results of breast cancer, colonic cancer, and lung cancer.

The results of these case studies further illustrate that RLSSLP exhibits good performance in identifying underlying disease-related miRNAs.

Discussion

In this study, we have presented a novel information fusion strategy called RLSSLP, which is based on regularized




Fig. 5 Network of top 40 miRNA candidates predicted by RLSSLP to be related to isolated diseases, namely, breast cancer, colonic cancer, and lung cancer.

framework, for discovering underlying associations between miRNAs and diseases. RLSSLP can predict isolated diseases and does not require negative training samples. The results of the 10-fold cross-validation and case studies for lung cancer, HCC, and breast cancer indicate that RLSSLP performs well in predicting miRNA–disease interactions. The AUC value obtained through cross-validation also demonstrated that RLSSLP performs better compared with other state-of-art approaches.

The favorable performance of RLSSLP can be mainly attributed to the following aspects. First, RLSSLP is a comprehensive prediction approach, which fuses various omics data that include the verified associations of miRNA–diseases, miRNAs–gene, and weighted gene–gene network. Second, RLSSLP combines two submodels to construct a more effective prediction framework for predicting miRNA–disease associations. Third, in RLSSLP, eigenvalue transformation technique can be used to improve the efficiency of the calculations.

Inevitably, the current version of RLSSLP has limitations. First, a more comprehensive similarity measurement for evaluating similarities for miRNAs and diseases can be adopted in the algorithm to improve the performance of RLSSLP. Second, the optimal value of parameter α can be obtained in a more satisfactory way. Finally, in RLSSLP, miRNA similarity measurement is based on miRNA–target associations. The number of known verified miRNA–target associations affects the prediction accuracy. The more the number of experimental validated miRNA targets, the more accurate the prediction is. Hence, the performance of the RLSSLP could be improved by obtaining more miRNA–target associations in the future. Nevertheless, RLSSLP exhibited good performance and can thus be considered a useful bioinformatics tool for biomedical research.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work is in part supported by National Natural Science Foundation of China (61702179, 61672356, 61572188), by Hunan Natural Science Foundation (2017JJ2239, 2016JJ2058), by Scientific Research Fund of Hunan Provincial Education Department (15B216), and by the Science and Technology Plan Project of Changsha (k1509003-11).

References

- 1 V. Ambros, *Nature*, 2004, **431**, 350–355.
- 2 D. P. Bartel, *Cell*, 2009, **136**, 215–233.
- 3 P. Paul, A. Chakraborty, D. Sarkar, M. Langthasa, M. Rahman, M. Bari, R. Singha, A. K. Malakar and S. Chakraborty, *J. Cell. Physiol.*, 2017, 9999, 1–12.
- 4 A. Ganju, S. Khan, B. B. Hafeez, S. W. Behrman, M. M. Yal lapu, S. C. Chauhan and M. Jaggi, *Drug Discov. Today*, 2017, **22**, 424–432.
- 5 Q. Jiang, Y. Hao, G. Wang, L. Juan, T. Zhang, M. Teng, Y. Liu and Y. Wang, *BMC Syst. Biol.*, 2010, **4**, S2.
- 6 H. Shi, J. Xu, G. Zhang, L. Xu, C. Li, L. Wang, Z. Zhao, W. Jiang, Z. Guo and X. Li, *BMC Syst. Biol.*, 2013, **7**, 101.
- 7 P. Xuan, K. Han, M. Guo, Y. Guo, J. Li, J. Ding, Y. Liu, Q. Dai, J. Li, Z. Teng, *et al.*, *PLoS One*, 2013, **8**, e70204.
- 8 H. Chen and Z. Zhang, *Sci. World J.*, 2013, **10**, 204658.
- 9 J. Q. Li, Z. H. Rong, X. Chen, G. Y. Yan and Z. H. You, *Oncotarget*, 2017, **8**, 21187.
- 10 Q. Jiang, G. Wang and Y. Wang, *2010 3rd International Conference On*, 2010, vol. 6, pp. 2270–2274.
- 11 J. Xu, C. X. Li, J. Y. Lv, Y. S. Li, Y. Xiao, T. T. Shao, X. Huo, X. Li, Y. Zou and Q. L. Han, *Mol. Cancer Ther.*, 2011, **10**, 1857–1866.
- 12 X. Chen, C. C. Yan, X. Zhang, Z. H. You, Y. A. Huang and G. Y. Yan, *Oncotarget*, 2016, **7**, 65257–65269.
- 13 Z. H. You, Z. A. Huang, Z. Zhu, G. Y. Yan, Z. W. Li, Z. Wen and X. Chen, *PLoS Comput. Biol.*, 2017, **13**, e1005455.
- 14 X. Chen, C. C. Yan, X. Zhang, Z. H. You, L. Deng, Y. Liu, Y. Zhang and Q. Dai, *Sci. Rep.*, 2016, **6**, 21106.
- 15 X. Chen, Z. C. Jiang, D. Xie, D. S. Huang, Q. Zhao, G. Y. Yan and Z. H. You, *Mol. BioSyst.*, 2017, **13**, 1202–1212.
- 16 X. Chen, C. C. Yan, X. Zhang, Z. Li, L. Deng, Y. Zhang and Q. Dai, *Sci. Rep.*, 2015, **5**, 13877.
- 17 Q. Zou, J. Li, L. Song, X. Zeng and G. Wang, *Briefings Funct. Genomics*, 2015, elv024.
- 18 X. Chen and G. Y. Yan, *Sci. Rep.*, 2014, **4**, 5501.
- 19 J. Luo, Q. Xiao, C. Liang, C. Liang and P. Ding, *IEEE Access*, 2017, **5**, 2503–2513.
- 20 R. Raymond and H. Kashima, *Mach Learn Discov.*, 2010, pp. 131–147.
- 21 Y. Li, C. Qiu, J. Tu, B. Geng, J. Yang, T. Jiang and Q. Cui, *Nucleic Acids Res.*, 2014, **42**, D1070–D1074.
- 22 S. D. Hsu, Y. T. Tseng, S. Shrestha, Y. L. Lin, A. Khaleel, C. H. Chou, C. F. Chu, H. Y. Huang, C. M. Lin, S. Y. Ho, *et al.*, *Nucleic Acids Res.*, 2014, **42**, D78–D85.
- 23 T. Vergoulis, I. S. Vlachos, P. Alexiou, G. Georgakilas, M. Maragkakakis, M. Reczko, S. Gerangelos, N. Koziris, T. Dalamagas and A. G. Hatzigeorgiou, *Nucleic Acids Res.*, 2011, **40**, D222–D229.
- 24 F. Xiao, Z. Zuo, G. Cai, S. Kang, X. Gao and T. Li, *Nucleic Acids Res.*, 2008, **37**, D105–D110.
- 25 I. Lee, U. M. Blom, P. I. Wang, J. E. Shim and E. M. Marcotte, *Genome Res.*, 2011, **21**, 1109–1121.
- 26 D. Wang, J. Wang, M. Lu, F. Song and Q. Cui, *Bioinformatics*, 2010, **26**, 1644–1650.
- 27 A. Schlicker, F. S. Domingues, J. Rahnenfuhrer and T. Lengauer, *BMC Bioinf.*, 2006, **7**, 302.
- 28 R. Rifkin and A. Klautau, *J. Mach. Learn. Res.*, 2004, **5**, 101–141.
- 29 Z. Xia, L. Y. Wu, X. Zhou and S. T. C. Wong, *BMC Syst. Biol.*, 2010, **4**, S6.
- 30 H. Kashima, T. Kato, Y. Yamanishi, M. Sugiyama and K. Tsuda, in *SDM*, 2009, pp. 1100–1111.
- 31 Q. Kuang, X. Xu, R. Li, Y. Dong, Y. Li, Z. Huang, Y. Li and M. Li, *Sci. Rep.*, 2015, **5**, 13867.



- 32 T. vanLaarhoven, S. B. Nabuurs and E. Marchiori, *Bioinformatics*, 2011, **27**, 3036–3043.
- 33 Z. Yang, F. Ren, C. Liu, S. He, G. Sun, Q. Gao, L. Yao, Y. Zhang, R. Miao, Y. Cao, Y. Zhao, Y. Zhong and H. Zhao, *BMC Genom.*, 2010, **11**, S5.
- 34 B. Xie, Q. Ding, H. Han and D. Wu, *Bioinformatics*, 2013, **29**, 638–644.
- 35 P. Leidinger, A. Keller and E. Meese, *Front. Genet.*, 2012, **2**, 104.
- 36 H. J. Yan, J. Y. Ma, L. Wang and W. Gu, *Med. Sci. Mon.*, 2015, **21**, 722.
- 37 C. Xu, S. Li, T. Chen, H. Hu, C. Ding, Z. Xu, J. Chen, Z. Liu, Z. Lei, H. T. Zhang, *et al.*, *Oncol. Rep.*, 2016, **35**, 497–503.
- 38 J. Tang, L. Li, W. Huang, C. Sui, Y. Yang, X. Lin, G. Hou, X. Chen, J. Fu, S. Yuan, *et al.*, *Canc. Lett.*, 2015, **364**, 33–43.
- 39 H. S. Jung, Y. R. Seo, Y. M. Yang, J. H. Koo, J. An, S. J. Lee, K. M. Kim and S. G. Kim, *Cell. Signal.*, 2014, **26**, 1456–1465.
- 40 M. V. Iorio, M. Ferracin, C. G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, E. Magri, M. Pedriali, M. Fabbri and M. Campiglio, *Cancer Res.*, 2005, **65**, 7065–7070.
- 41 L. Ma, G. Li, Z. Wu and G. Meng, *Med. Oncol.*, 2014, **31**, 773.
- 42 A. Schwickert, E. Weghake, K. Brüggemann, A. Engbers, B. F. Brinkmann, B. Kemper, J. Seggewiß, C. Stock, K. Ebnet, L. Kiesel, *et al.*, *PLoS One*, 2015, **10**, e0143993.
- 43 H. X. Wu, G. M. Wang, X. Lu and L. Zhang, *Eur. Rev. Med. Pharmacol. Sci.*, 2017, **21**, 108–114.

